These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 12124479)
1. Estimating uptake in liver and abdominal tumours for radionuclide therapy dosimetry. Bartlett ML; Macfarlane DJ Nucl Med Commun; 2002 Aug; 23(8):743-8. PubMed ID: 12124479 [TBL] [Abstract][Full Text] [Related]
2. Strengths and Weaknesses of a Planar Whole-Body Method of (153)Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry. Plyku D; Loeb DM; Prideaux AR; Baechler S; Wahl RL; Sgouros G; Hobbs RF Cancer Biother Radiopharm; 2015 Nov; 30(9):369-79. PubMed ID: 26560193 [TBL] [Abstract][Full Text] [Related]
3. A pilot study on the feasibility of real-time calculation of three-dimensional dose distribution for (153)Sm-EDTMP radionuclide therapy based on the voxel S-values. Feng G; Lixin C; Xiaowei L; Tsao SY; Weiguang Z; Wei F Cancer Biother Radiopharm; 2010 Jun; 25(3):345-52. PubMed ID: 20578840 [TBL] [Abstract][Full Text] [Related]
4. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. Brenner W; Kampen WU; Kampen AM; Henze E J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521 [TBL] [Abstract][Full Text] [Related]
5. The importance of BMI in dosimetry of Fallahpoor M; Abbasi M; Asghar Parach A; Kalantari F Appl Radiat Isot; 2017 Jun; 124():1-6. PubMed ID: 28284122 [TBL] [Abstract][Full Text] [Related]
6. Lipiodol solution of 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: preclinical study in a rabbit liver cancer model. Paeng JC; Jeong JM; Yoon CJ; Lee YS; Suh YG; Chung JW; Park JH; Chung JK; Son M; Lee MC J Nucl Med; 2003 Dec; 44(12):2033-8. PubMed ID: 14660730 [TBL] [Abstract][Full Text] [Related]
7. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. Dewaraja YK; Wilderman SJ; Ljungberg M; Koral KF; Zasadny K; Kaminiski MS J Nucl Med; 2005 May; 46(5):840-9. PubMed ID: 15872359 [TBL] [Abstract][Full Text] [Related]
8. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma. Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951 [TBL] [Abstract][Full Text] [Related]
9. Daily ultrasound-based image-guided targeting for radiotherapy of upper abdominal malignancies. Fuss M; Salter BJ; Cavanaugh SX; Fuss C; Sadeghi A; Fuller CD; Ameduri A; Hevezi JM; Herman TS; Thomas CR Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1245-56. PubMed ID: 15234062 [TBL] [Abstract][Full Text] [Related]
10. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP. van Rensburg AJ; Alberts AS; Louw WK J Nucl Med; 1998 Dec; 39(12):2110-5. PubMed ID: 9867152 [TBL] [Abstract][Full Text] [Related]
11. [The measurement of 153Sm-EDTMP bone uptake rate and its relationship with therapeutic effect]. Li L; Liang Z; Deng H; Li Y; Zhang X; Yang X Hua Xi Yi Ke Da Xue Xue Bao; 2001 Sep; 32(3):446-8. PubMed ID: 12536590 [TBL] [Abstract][Full Text] [Related]
12. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487 [TBL] [Abstract][Full Text] [Related]
13. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer. Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596 [TBL] [Abstract][Full Text] [Related]
14. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Otte A; Jermann E; Behe M; Goetze M; Bucher HC; Roser HW; Heppeler A; Mueller-Brand J; Maecke HR Eur J Nucl Med; 1997 Jul; 24(7):792-5. PubMed ID: 9211767 [TBL] [Abstract][Full Text] [Related]
15. Treatment planning in PRRT based on simulated PET data and a PBPK model. Determination of accuracy using a PET noise model. Hardiansyah D; Guo W; Attarwala AA; Kletting P; Mottaghy FM; Glatting G Nuklearmedizin; 2017 Feb; 56(1):23-30. PubMed ID: 27885372 [TBL] [Abstract][Full Text] [Related]
16. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Forrer F; Uusijärvi H; Waldherr C; Cremonesi M; Bernhardt P; Mueller-Brand J; Maecke HR Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1257-62. PubMed ID: 15197500 [TBL] [Abstract][Full Text] [Related]
17. Advantage of 188Re-radiopharmaceuticals in hepatocellular cancer and liver metastases. Liepe K; Kotzerke J; Lambert B J Nucl Med; 2005 Aug; 46(8):1407-8; author reply 1407-8. PubMed ID: 16085601 [No Abstract] [Full Text] [Related]
18. Role of lipid-soluble complexes in targeted tumor therapy. Thakur ML; Coss R; Howell R; Vassileva-Belnikolovska D; Liu J; Rao SP; Spana G; Wachsberger P; Leeper DL J Nucl Med; 2003 Aug; 44(8):1293-300. PubMed ID: 12902421 [TBL] [Abstract][Full Text] [Related]
19. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors. Sarfaraz M; Kennedy AS; Cao ZJ; Sackett GD; Yu CX; Lodge MA; Murthy R; Line BR; Van Echo DA Med Phys; 2003 Feb; 30(2):199-203. PubMed ID: 12607837 [TBL] [Abstract][Full Text] [Related]
20. Synthesis of 188 Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer. Lee YS; Jeong JM; Kim YJ; Chung JW; Park JH; Suh YG; Lee DS; Chung JK; Lee MC Nucl Med Commun; 2002 Mar; 23(3):237-42. PubMed ID: 11891481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]